Cargando…

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion

Classical Hodgkin lymphoma (CHL) is unusually sensitive to PD1 inhibition and PDL1 is highly expressed on CHL cells and in the tumor microenvironment. This could be interpreted as evidence of exhaustion, but paradoxically, PD1(+) lymphocyte infiltration does not predict response to PD1 inhibitors an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Joseph G., Truelove, Edward, Clear, Andrew, Calaminici, Maria, Gribben, John G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Hodgkin Lymphoma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071123/ https://www.ncbi.nlm.nih.gov/pubmed/35833296 http://dx.doi.org/10.3324/haematol.2022.280014

Ejemplares similares

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies
por: Boot, Max V., et al.
Publicado: (2022)

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023)

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2023)

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022)

Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
por: Leivonen, Suvi-Katri, et al.
Publicado: (2023)

Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
por: Fisher, Kevin E., et al.
Publicado: (2022)

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
por: Isaev, Keren, et al.
Publicado: (2022)

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
por: Song, Joo Y., et al.
Publicado: (2023)

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
por: Ghione, Paola, et al.
Publicado: (2022)

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
por: Barraclough, Allison, et al.
Publicado: (2023)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma
por: Mularoni, Valentina, et al.
Publicado: (2023)

Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation
por: Koch, Karoline, et al.
Publicado: (2022)

Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
por: Torres, Armando N. Bastidas, et al.
Publicado: (2021)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy
por: Demel, Uta M., et al.
Publicado: (2022)

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
por: Kameda, Takuro, et al.
Publicado: (2023)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
por: Veloza, Luis, et al.
Publicado: (2022)

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
por: Decombis, Salomé, et al.
Publicado: (2022)

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
por: Svoboda, Jakub, et al.
Publicado: (2021)

CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development
por: Korona, Boguslawa, et al.
Publicado: (2022)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
por: Rai, Shinya, et al.
Publicado: (2022)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database
por: Liu, Xin, et al.
Publicado: (2023)

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
por: Kostakoglu, Lale, et al.
Publicado: (2021)

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
por: Arribas, Alberto J., et al.
Publicado: (2022)

Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B-cell lymphomas
por: López, Cristina, et al.
Publicado: (2022)

DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
por: Qiu, Lianqun, et al.
Publicado: (2022)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS
por: Wai, Cho Mar Myint, et al.
Publicado: (2022)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
por: García-Sancho, Alejandro Martín, et al.
Publicado: (2022)

Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
por: Isaksen, Kathrine T., et al.
Publicado: (2023)

A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas
por: Wang, Xiaoxiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_quet0712kar14frjkrljvf0u1e